Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of CA125 to curative effect evaluation of primary liver cancer stereotactic radiotherapy

A technology for CA125 and primary liver cancer, which is applied in the direction of measuring devices, instruments, scientific instruments, etc., can solve the problems that primary liver cancer does not have good diagnostic performance and prognosis evaluation performance

Active Publication Date: 2020-03-24
WENZHOU MEDICAL UNIV
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, the clinical standard of CA125 higher than 35.0 U / ml does not have good diagnostic and prognostic performance for primary liver cancer

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of CA125 to curative effect evaluation of primary liver cancer stereotactic radiotherapy
  • Application of CA125 to curative effect evaluation of primary liver cancer stereotactic radiotherapy
  • Application of CA125 to curative effect evaluation of primary liver cancer stereotactic radiotherapy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0017] Example 1. Evaluation of diagnostic sensitivity of tumor markers in patients with liver cancer

[0018] Collected the medical records of patients with liver cancer treated with SBRT for the first time in tertiary hospitals from July 2012 to December 2018, a total of 598 cases (the same patient was admitted to the hospital multiple times, counted as 1 case), excluding SBRT combined with chemotherapy, targeted therapy, etc. There were 202 patients with other treatment methods, and a total of 396 patients with liver cancer who only received SBRT were obtained. At the end of December 2018, 396 patients were followed up for the last time, and the SPSS database was completed. According to the concentration of tumor markers AFP, CEA, CA125, CA15-3, CA19-9 and CA724 in the serum of patients before and 6 months after SBRT treatment, evaluate the effect of each tumor marker before and 6 months after SBRT treatment in patients with liver cancer sensitivity.

[0019] In the popula...

Embodiment 2

[0023] Example 2. For the population whose tumor markers were within the normal range before SBRT treatment, which tumor markers were screened for differences before and after SBRT treatment

[0024] In Example 1, only alpha-fetoprotein AFP has a high sensitivity in diagnosing liver cancer. Since more than half of liver cancer patients have normal levels of tumor markers before and after SBRT treatment, can another method be used for liver cancer patients with negative tumor markers? To evaluate the efficacy of SBRT treatment is our research interest.

[0025]In order to answer the above questions, we screened out the population of 396 liver cancer patients whose tumor marker concentrations were within the normal range before SBRT treatment and whose corresponding tumor marker concentrations were detected 6 months after treatment. The paired rank sum test was used to analyze the changes of AFP, CEA, CA125, CA15-3, CA19-9, and CA724 in this population before and 6 months after ...

Embodiment 3

[0030] Example 3. Evaluation of the influence of the change ratio of CA125 at 6 months after SBRT treatment on the prognosis of 1 to 5 years

[0031] In Example 2, we found that in patients with primary liver cancer whose tumor markers were within the normal reference range before SBRT treatment, only AFP and CA125 had significant differences before and after SBRT treatment. In this example, we calculated the ratio of changes in AFP and CA125 after 6 months of SBRT compared with before treatment in patients with primary liver cancer who were followed up for 1 year, 2 years, 3 years and 5 years [(6 months Concentration-concentration before treatment) / concentration before treatment] in the survival group and death group, the results showed that AFP had no change before and after treatment; while the change ratio of CA1256 months was compared to 1 year, 2 years, 3 years and 5 years The follow-up prognosis was affected, and there were significant differences between the survival g...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Sensitivityaaaaaaaaaa
Sensitivityaaaaaaaaaa
Sensitivityaaaaaaaaaa
Login to View More

Abstract

The invention discloses an application of CA125 as curative effect evaluation molecular marker to stereotactic radiotherapy (SBRT) of a primary liver cancer patient with a tumor marker negative (CA125 is less than 35.0 U / ml). For CA125 negative primary liver cancer patients, if the serum CA125 concentration is higher than that before treatment 6 months after SBRT treatment, the prognosis is predicted to be poor. When the rising ratio is higher than 150%, the prognosis of the patient is poor for one year and two years; and when the rising ratio is higher than 23%, the prognosis of the patientis poorer for 3 years and 5 years. The invention provides a method for prognosis evaluation of CA125-negative primary liver cancer patients after SBRT treatment for 1-5 years, and the method has important significance in improving the survival rate of liver cancer and reducing the death rate.

Description

technical field [0001] The invention belongs to the applied field of molecular biology. Specifically, the present invention relates to the application of cancer antigen CA125 in the evaluation of the curative effect of stereotactic radiotherapy for primary liver cancer patients with negative tumor markers. Background technique [0002] Primary liver cancer is one of the most common malignant tumors in the world. According to global cancer statistics in 2018, there were more than 841,000 newly diagnosed primary liver cancers and 782,000 related deaths. It accounts for about 50% of the total cases and deaths worldwide. Primary liver cancer is also one of the most common malignant tumors in China, and its morbidity and mortality rank the fourth and second among malignant tumors in my country, respectively. At present, there are various treatment methods for primary liver cancer. Surgical treatment includes radical surgical resection and liver transplantation; non-surgical tre...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/574
CPCG01N33/57488
Inventor 刘晓冬
Owner WENZHOU MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com